Venture capital funding for digital health startups is on an upswing, fueled by an AI-powered rebound following a post-pandemic reset in 2023.
Digital health companies raised $7.4 billion in the first half of 2026, up $1 billion compared to the first half of 2026 ($6.4 billion raised), according to Rock Health's analysis of digital health deals in the first half of 2026. There were 244 deals in H1 2026. Investors poured $3.2 billion into the sector in Q2, just shy of Q1’s $4.2 billion.
Building on trends from last year and into Q1 this year, capital is concentrating among a small number of megadeals as venture capital investors place their bets on innovative digital health companies, Rock Health researchers Ashwini Nagappan, Jason Lei and Maddie Knowles wrote.
In the first half of 2026, 19 companies raised 20 megadeals, or financings of $100 million and higher, representing 45% of all capital invested. Over 8% of deals absorbed nearly half of all capital deployed. Some of those megadeals included Whoop ($575 million), OpenEvidence ($250 million), Grow Therapy ($150 million), Verily ($300 million), Talkiatry ($210 million), eMed ($200 million), Forus ($160 million) and Aidoc ($150 million).
There were also some back-to-back deals such as employer-focused care navigator Garner Health securing a $100 million series E just three months after its $118 million series D, while clinical AI platform Aidoc clinched its second $150 million check in less than a year.
Mental health continues to be the top-funded clinical indication (note above-mentioned funding rounds for Talkiatry and Grow Therapy). Jimini Health also raised $17 million while The Path picked up $14.3 million. Weight management and obesity is the second most-funded clinical indication, driven by the insatiable GLP-1 market and the ecosystem scaling around it. The sector saw three megadeals in 2026: eMed ($200 million), Nourish ($100 million), and Midi ($100 million).
The success of GLP-1s is drawing investor interest to adjacent peptide categories, including experimental peptides for wellness and longevity. Superpower raised $30 million, while Protocole picked up $6 million and Feel Peptides nabbed $3 million.
As AI technology rapidly advances, its resetting expectations, reshaping the funding environment and changing the competitive landscape.
"As AI changes what’s easy to build, competitive advantage increasingly comes from qualities that are difficult to replicate," Rock Health researchers wrote in the report.
"As foundation models improve and AI capabilities become easier to build, technical differentiation is becoming harder to sustain. Investors and buyers are not asking, “Who has AI?” but instead, “Who has something AI alone can’t provide?” researchers wrote.
Rock Health examined how durable advantage for digital health startups is evolving in the AI era. Researchers identified four key themes as startups strive to build defensible moats: domain expertise, "owning" more of the workflow, hands-on delivery and strong partnerships and network effects.
"As AI lowers the barriers to building, founders with deep experience inside the healthcare organizations they’re selling to often have a clearer view of where the most meaningful (and solvable) problems exist," Rock Health researchers wrote, based on feedback from investors
"None of us know what the world is going to look like two years from now. The primary attribute of any pitch that is most fundamental to diligence is the founder. Founder-market fit matters a lot right now. We’ve seen real advantages with founders who understand not just the business function they’re trying to improve, but also the culture and conditions that shape how their customers operate," Sean Doolan, Virtue founder and investor, said, as quoted in the report.
Many digital health companies are now competing for greater ownership of the healthcare operating layer. Companies are looking to scale as AI makes it easier to build competing, single-use-case products and as agentic AI increases the value of orchestrating more of the workflow. Owning more of the workflow gives startups more context, making it easier to coordinate across tasks.
Many startups also are trying to develop a competitive advantage based on service after the sale. Some startups are investing in forward-deployed engineers (FDEs). "The rationale is that launching highly customizable systems requires white-glove service, one that sends FDEs to work directly with customers on an ongoing basis and co-develop custom workflows from within the client’s environment," Rock Health researchers wrote.
Commure and Qualified Health have made FDEs a core part of their go-to-market, according to Rock Health.
Strategic partnerships also have become a key differentiator for startups. "Vendors that partner with organizations and standards buyers already trust can build on existing credibility rather than earn it entirely on their own. And every new integration or endorsement can make a product more trusted and harder to replace, giving customers even more reason to stay within the same ecosystem," Rock Health researchers wrote.
Abridge has tapped several new partners, linking up with Nvidia on clinical foundation models, American Health Information Management Association (AHIMA) on coding standards, the American Diabetes Association (ADA), and the American Academy of Family Physicians (AAFP) on clinical validation, and companies like Artisight and hellocare.ai on smart-room integrations. OpenEvidence has inked partnerships with medical societies and publishers.
The digital health sector has yet to see an initial public offering in 2026, but several companies are prepping to go public including Oura, Whoop and Virta Health. Other companies that the industry is keeping an eye on include Maven Clinic, Devoted Health and Spring Health.
As another exit strategy, many digital health companies are looking for acquirers. Digital health M&A is on an upswing, with 115 acquisitions in the first half of this year, just above 2025’s pace of 199 annual deals and well above 2024’s 121, Rock Health noted. Revenue cycle management is an active sector for consolidation. So far in 2026, IKS Health purchased TruBridge to extend its RCM platform to rural communities, Med-Metrix completed back-to-back deals for Vitalware and CanAide, and Innovaccer folded CaduceusHealth into its platform.
Private equity players also placed their bets. Matt Holt’s Thoreau Group signed a $12 billion agreement to acquire RCM player Ensemble Health.